4.4 Article

Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19

Journal

JACC-CLINICAL ELECTROPHYSIOLOGY
Volume 7, Issue 1, Pages 16-25

Publisher

ELSEVIER
DOI: 10.1016/j.jacep.2020.07.016

Keywords

azithromycin; COVID-19; hydroxychloroquine; QT prolongation; torsades de pointes

Ask authors/readers for more resources

This study characterized QTc prolongation in hospitalized COVID-19 patients treated with HCQ/AZM. Several clinical factors were associated with greater QTc prolongation, but changes in QTc were not linked to increased risk of death.
OBJECTIVES This study aimed to characterize corrected QT (QTc) prolongation in a cohort of hospitalized patients with coronavirus disease-2019 (COVID-19) who were treated with hydroxychloroquine and azithromycin (HCQ/AZM). BACKGROUND HCQ/AZM is being widely used to treat COVID-19 despite the known risk of QT interval prolongation and the unknown risk of arrhythmogenesis in this population. METHODS A retrospective cohort of COVID-19 hospitalized patients treated with HCQ/AZM was reviewed. The QTc interval was calculated before drug administration and for the first 5 days following initiation. The primary endpoint was the magnitude of QTc prolongation, and factors associated with QTc prolongation. Secondary endpoints were incidences of sustained ventricular tachycardia or ventricular fibrillation and all-cause mortality. RESULTS Among 415 patients who received concomitant HCQ/AZM, the mean QTc increased from 443 +/- 25 ms to a maximum of 473 +/- 40 ms (87 [21%] patients had a QTc >= 500 ms). Factors associated with QTc prolongation >= 500ms were age (p < 0.001), body mass index <30 kg/m(2) (p 0.005), heart failure (p < 0.001), elevated creatinine (p 0.005), and peak troponin (p < 0.001). The change in QTc was not associated with death over the short period of the study in a population in which mortality was already high (hazard ratio: 0.998; p = 0.607). No primary high-grade ventricular arrhythmias were observed. CONCLUSIONS An increase in QTc was seen in hospitalized patients with COVID-19 treated with HCQ/AZM. Several clinical factors were associated with greater QTc prolongation. Changes in QTc were not associated with increased risk of death. (C) 2021 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available